DIVISLAB2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member DIVISLAB2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member DIVISLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-10-012020-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DIVISLAB2020-10-012020-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2020-04-01 2021-03-31 2021-01-23 INR Lakhs Third quarter Single segment Pharmaceuticals 2020-10-01 2020-12-31 Unaudited Consolidated 17014400000.00 193200000.00 17207600000.00 6803200000.00 16100000.00 -1553300000.00 2336000000.00 2700000.00 681800000.00 2500300000.00 10786800000.00 6420800000.00 0.00 6420800000.00 1447800000.00 266800000.00 1714600000.00 0.00 4706200000.00 0.00 0.00 0.00 0.00 4706200000.00 3300000.00 4709500000.00 4706200000.00 0.00 4709500000.00 0.00 530900000.00 2 17.73 17.73 0.00 0.00 17.73 17.73 1.The above Statement of Consolidated unaudited financial results for the quarter and nine months ended 31st December, 2020 are prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under section 133 of the Companies Act 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 6th February, 2021. The same were also subjected to “limited review” by the Auditors of the company and their report contains no qualification. n2.The consolidated financial results include the financial results of Divi’s Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG. n3.The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes single reportable business segment as per Ind AS 108. n4.The Group does not have any discontinued operations and the Profit for the period / year represents the Profits from continuing operations only. n5.The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. n6.Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year’s classification n7.Details of forex gain/(loss) are as given below: n (Rs.in Lakhs) ntQuarter endedtNine-months endedtYear ended nt31.12.2020t30.09.2020t31.12.2019t31.12.2020t31.12.2019t31.03.2020 nForex gain/(loss)t253t(1563)t1796t(829)t2501t8211 nForex gain has been included in Other Income and loss has been included in Other Expenses Single segment 2020-04-01 2020-12-31 Unaudited Consolidated 51812100000.00 429500000.00 52241600000.00 16838300000.00 56500000.00 532300000.00 6106800000.00 6600000.00 1855100000.00 6880500000.00 32276100000.00 19965500000.00 0.00 19965500000.00 4793700000.00 349100000.00 5142800000.00 0.00 14822700000.00 0.00 0.00 0.00 0.00 14822700000.00 18900000.00 14841600000.00 14822700000.00 0.00 14841600000.00 0.00 530900000.00 2 55.84 55.84 0.00 0.00 55.84 55.84 Other Expenses 2500300000.00 Other Expenses 6880500000.00